Business
WILLOW ANNOUNCES SUCCESSFUL COMPLETION OF R&D PROGRAM ON COST-EFFECTIVE, SUSTAINABLY PRODUCED UDCA
WILLOW ANNOUNCES SUCCESSFUL COMPLETION OF R&D PROGRAM ON COST-EFFECTIVE, SUSTAINABLY PRODUCED...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n \n \n \n WILLOW ANNOUNCES SUCCESSFUL COMPLETION OF R&D PROGRAM ON COST-EFFECTIVE, SUSTAINABLY PRODUCED UDCA\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n WILLOW ANNOUNCES SUCCESSFUL COMPLETION OF R&D PROGRAM ON COST-EFFECTIVE, SUSTAINABLY PRODUCED UDCA\n \n \n Canada NewsWire\n \n \n \n \n \n Company's BioOxi™ Platform solves for selective C-H hydroxylation, one of the \"Holy Grails\" of chemistry\n \n \n \n \n BioOxi is broadly applicable to manufacturing of intermediates and active pharmaceutical ingredients, particularly for steroid applications\n \n \n \n \n \n SUNNYVALE, Calif.\n \n \n ,\n \n \n Sept. 6, 2023\n \n \n /CNW/ - Willow Biosciences Inc. (\"\n \n Willow\n \n \") (TSX: WLLW; OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, announces that it has successfully completed research and development on its program to produce ursodeoxycholic acid (\"UDCA\"), a large volume active pharmaceutical ingredient (\"API\") used in nutraceutical and pharmaceutical products. UDCA has applications as a medication for management and treatment of cholestatic liver disease and gallstone conditions, and as an intermediate for production of tauroursodeoxycholic acid (TUDCA), a key API in a combination therapy recently approved in\n \n Canada\n \n and\n \n the United States\n \n for treatment of amyotrophic lateral sclerosis (ALS).\n \n \n \n \n \n \n \n \n \n \n BioOxi's Breakthrough Technology Provides Commercially Economical Enzymatic Production of UDCA\n \n \n \n Through this partnered program with Sandhill One, LLC (\"Sandhill\"), Willow has now optimized a proprietary enzyme vital to the development of UDCA while solving for selective C-H hydroxylation at industrial scale - often referred to as one of the \"Holy Grails\" of chemistry. This breakthrough was made possible by Willow's BioOxi technology, and we believe marks the first example of commercially relevant productivities with this class of ...